Role of body-surface area in Cisplatin pharmacokinetics

Li Liu, MD

University of Pennsylvania Cancer
Last Modified: May 13, 2001

Share article


Presenter: F. de Jongh
Affiliation: Rotterdam Cancer Institute, Rotterdam, Netherlands

Background:

    Dosages of anticancer drugs are usually calculated on the basis of a uniform standard, the body surface area (BSA). Although many physiological functions are proportionate to BSA, overall drug clearance is only partially related to this parameter. Consequently, following administration of equivalent drug dosages based on BSA, a wide variability in plasma drug concentrations can be found between patients, as a result of which some patients experience little toxicity while others may show severe toxic symptoms.

Materials and Methods:

  • A total of 268 adult patients with advanced solid tumors who were treated with cisplatin based chemotherapy were included in this retrospective study
  • Cisplatin was given either weekly or every 3 weeks
  • Pharmocokenitics of cisplatin was studied

Results:

  • The relationship between the AUCs of unbound and total cisplatin was linear
  • The interpatient variability of the plasma clearance of unbound Cisplatin (Clfree) was 25.6%, whereas the BSA variability was 10.4%
  • There was no strong correlation between Clfree and BSA

Authors' Conclusions

  • There appeared to be a high interpatient variability relative to variation in observed BSA
  • BSA-based dosing of Cisplatin may not be necessary

Clinical/Scientific Implications:

  • Since a high proportion of the patients received combination therapy with other chemotherapy agents, this study should be interpreted with caution
  • A clear pharmacokinetic/pharmacodynamic correlation has been demonstrated for some anticancer drugs, and this relationship provides a background against which rational dose optimisation should be implemented for individual patients
ASCO Abstract 266

Saturday | Sunday | Monday | Tuesday

OncoLink ASCO 2001 coverage is provided by an unrestricted educational grant from Amgen


News
Normal Breast Protein Linked to Cancer Development

Feb 21, 2012 - Trefoil protein, which maintains the integrity of the epithelial surface in the normal breast, is highly expressed in well-differentiated tumors, correlating with low histological grade, and also has an expression profile which is consistent with a role in breast cancer progression and metastasis, according to a study published in the March issue of The American Journal of Pathology.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More